<DOC>
	<DOCNO>NCT00010348</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety total body irradiation post-transplant cyclosporine mycophenolate mofetil high-risk patient human immunodeficiency virus-1 . II . Determine whether regimen result stable mixed donor lymphocyte chimerism ( 5-95 % donor CD3 ) patient population . III . Determine kinetics immune reconstruction follow treatment regimen patient population . IV . Determine effect treatment regimen viral load patient population .</brief_summary>
	<brief_title>Study Total Body Irradiation Combination With Allogeneic Peripheral Blood Stem Cell Bone Marrow Transplantation Followed By Cyclosporine Mycophenolate Mofetil High Risk-Patients With Human Immunodeficiency Virus-1</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive oral IV cyclosporine 2-3 time daily Days -1 50 . Patients undergo total body irradiation follow allogeneic peripheral blood stem cell bone marrow transplantation Day 0 ( assume donor available ) . Beginning within 6 hour transplantation , patient receive oral mycophenolate mofetil every 12 hour Day 27 . Patients unstable level chimerism may receive 1-2 donor lymphocyte infusion . Patients follow Days 14 , 28 , 56 , 80 , 180 , 360 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis human immunodeficiency virus1 responsive highly active antiretroviral therapy ( HAART ) ; treat HAART least past 6 month ; viral load le 50 copies/mL plasma ; CD4 count le 100/mm3 Lymphoma HIVassociated malignancy allow follow criterion : malignancy complete remission good partial remission , define significant reduction disease therapy evidence continue tumor growth ; viral load decrease least 1.5 log OR le 5,000 copies/mL plasma HAART ; CD4 count allow great 100/mm3 HLA genotypically identical donor available ( 75 year age ) Prior/Concurrent Therapy No concurrent growth factor mycophenolate mofetil administration ; concurrent continuation antiretroviral therapy require Patient Characteristics Life expectancy : At least 30 day Other : No positive serology Toxoplasma gondii ; disease organ dysfunction would preclude survival ; pregnant nursing ; fertile patient must use effective contraception 1 year study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>human immunodeficiency virus infection</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>viral infection</keyword>
</DOC>